GET DAILY SIGNALSPaysign (PAYS) Drops -38% in 30 Days Despite Record Q3 Results
Key Takeaways
- Paysign (PAYS) shares fell roughly 38% over the past 30 days, from about $15.16 to near $9.45, even after the company reported record third-quarter results.
- The decline was driven mainly by a large plasma customer's decision to move payment processing for 113 collection centers to another provider, pressuring future revenue expectations.
- Third-quarter revenue rose 43% year over year to $30.8 million, while diluted EPS of $0.11 exceeded analyst estimates.
- Patient affordability (pharmaceutical co-pay assistance) more than doubled to $16.6 million and is now the company's primary growth engine.
- Over the last quarter, shares are also down roughly 27%, following a rally to a 52-week high near $16 in October and a sharp November reversal.
- Analysts trimmed their price targets, with DA Davidson lowering its target to $14 and Maxim Group downgrading the stock after the customer disclosure.
- For additional detail on the ticker, you can explore Price Targets, Earnings, and Forecast pages.
- To see how automated strategies are positioned across the market, explore Trending AI Robots.
Company Overview and Market Position
Paysign, Inc. is a fintech and payment-processing company operating two complementary businesses. Its legacy segment provides prepaid card and digital payout solutions used primarily by blood-plasma collection centers to compensate donors. Its faster-growing segment, patient affordability, administers pharmaceutical co-pay assistance programs that help patients afford branded medications while helping manufacturers manage costs. The company also operates donor engagement technology and is developing Apherion, a donor-management software platform. Investors follow PAYS for its shift toward higher-margin pharmaceutical revenue, expanding margins, and a balance sheet that ended September with $34.5 million in unrestricted cash and no bank debt. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, PAYS declined approximately 37.7%, from a closing price of $15.16 on October 14 to near $9.45 in mid-November. The move was concentrated in a few sessions: after closing at $14.69 on November 6, the stock fell about 15% on November 9 and roughly 19% the following session, settling near $9.48 by November 11.
The quarterly picture is more complex. Measured from mid-August, shares are down roughly 27%, but that net change masks a volatile round trip. The stock climbed from about $13 in mid-August to a 52-week high near $16.15 in October as investor enthusiasm around the patient affordability business grew, then reversed sharply when the plasma customer transition was disclosed alongside third-quarter earnings.
What Drove the Recent Decline
The sharp decline followed Paysign's third-quarter report on November 9. The operating results were strong: revenue increased 43% year over year to $30.8 million, patient affordability revenue rose about 110% to $16.6 million, gross margin expanded to 64.7%, and net income grew more than 200% to $6.7 million, or $0.11 per diluted share, beating consensus estimates. Management also raised its full-year profitability guidance. I reviewed the numbers against AI Daily Buy/Sell Signals for additional context on momentum.
Investors focused instead on a separate disclosure. A large plasma customer said it would move payment processing for 113 of Paysign's 562 centers to an existing banking partner by the end of 2026. Those centers generated roughly $11.3 million of trailing revenue and $5.2 million of gross profit, and the company expects the transition to reduce fourth-quarter revenue by about $1.5 million. The announcement weighed on 2027 growth assumptions and prompted DA Davidson to lower its price target to $14 and Maxim Group to downgrade the shares, accelerating the selloff.
Performance Drivers Over the Quarter
The quarter's trajectory was shaped by a shift in business mix. Strong second-quarter results in early August, together with accelerating patient affordability growth, powered a multi-month rally as pharmaceutical revenue became a larger share of the mix and margins expanded. The patient affordability segment added programs throughout the year and increased revenue per program roughly 32% year over year to $99,524, reinforcing the bull case.
The November reversal reflected renewed scrutiny of the mature plasma business. With the loss of 113 centers, Paysign expects to exit 2026 serving 445 to 450 plasma centers, down from 562 at the end of September. While management said the decision was not service-related and expects to offset the loss over time, the disclosure highlighted concentration and customer-consolidation risk in the legacy segment, reversing much of the earlier gains.
Key Factors to Watch Going Forward
The most important near-term question is whether Paysign can replace the lost plasma centers and sustain patient affordability momentum into 2027. Investors will watch full-year 2026 results against management's revenue outlook of $114 million to $117 million and its raised profit targets, as well as 2027 guidance for clarity on the plasma revenue gap. The pace of new patient affordability program additions, the timing of regulatory feedback on the Apherion software platform, and any further plasma customer consolidation will also influence sentiment. Changes to co-pay assistance rules or competitive dynamics in payment processing remain key risks to monitor.
Exploring Tickeron’s AI Tools
In my own analysis, I frequently turn to Tickeron’s AI Trading Bots to test how different automated strategies might respond to events like the recent customer shift at PAYS. The platform offers a range of bots with varying timeframes and risk profiles, which helps me quickly compare scenarios without building models from scratch. It is one more data point I consider alongside traditional fundamentals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PAYS in downward trend: price dove below 50-day moving average on November 09, 2026
PAYS moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend. In 29 of 32 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PAYS as a result. In 69 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for PAYS turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 34 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
The 10-day moving average for PAYS crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PAYS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where PAYS advanced for three days, in 251 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
PAYS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 191 of 245 cases where PAYS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 39 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. PAYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.933) is normal, around the industry mean (16.275). P/E Ratio (48.904) is within average values for comparable stocks, (45.369). Projected Growth (PEG Ratio) (1.840) is also within normal values, averaging (3.696). Dividend Yield (0.000) settles around the average of (0.430) among similar stocks. P/S Ratio (7.310) is also within normal values, averaging (103.897).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of payment solutions
Industry ComputerCommunications
Advertisement